Trial Profile
A Retrospective study of dabrafenib and trametinib combination therapy in V600 BRAF-mutated advanced/metastatic melanoma patients in a real-life setting at Milan
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2016 New trial record